Kirk E. Hevener

Identification of Small Molecules Exhibiting Oxacillin Synergy through a Novel Assay for Inhibition of <i>vraTSR</i> Expression in Methicillin-Resistant Staphylococcus aureus

Hit-to-Lead: Hit Validation and Assessment

Comparison of radii sets, entropy, <scp>QM</scp> methods, and sampling on <scp>MM‐PBSA</scp>, <scp>MM‐GBSA</scp>, and <scp>QM/MM‐GBSA</scp> ligand binding energies of <scp><i>F</i></scp><i>. tularensis</i> enoyl‐<scp>ACP</scp> reductase (<scp>F</scp>abI)

Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI)

Hit Identification and Optimization in Virtual Screening: Practical Recommendations Based on a Critical Literature Analysis

Fragment-Based Drug Discovery Using a Multidomain, Parallel MD-MM/PBSA Screening Protocol

Synergistic Inhibitor Binding to the Papain‐Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications

High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes

Structural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of <i>Francisella tularensis</i> Enoyl Reductase (FabI) Inhibitors